Because EVI1 overexpression is associated with poor responsiveness to chemotherapy in AML, we next asked whether experimental expression of EVI1 would render U937 cells more resistant to agents routinely used to treat this disease. This evidence concerns the gene MECOM and acute myeloid leukemia.